CDT Equity Inc. (CDT) stock
Close on Nov 11, 2026Market cap $401.20KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $401.20K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$37.15M
- EPS, diluted
- -$1177.89
- Book value per share
- $193.42
- Diluted shares
- 1M
Trading
- Previous close
- $0.56
- Open
- $0.48
- Day's range
- $0.45 – $0.56
- Volume
- 1,429,886
- Average volume (20 days)
- 3,213,247
- Beta (5 years)
- 3.58
- 52-week range
- $0.17 – $355000.00
- RSI (14 days)
- 37.4
- Volatility (1 year)
- 9008.8%
- Relative volume
- 1.81×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDT | S&P 500 | Difference | CDT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -29.0% | -2.4% | −26.6 pts | ||
| 3 months | -100.0% | -1.2% | −98.8 pts | ||
| Year to date | -100.0% | +12.3% | −112.3 pts | ||
| 1 year | -100.0% | +12.4% | −112.4 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -99.9% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CDT Equity filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- News
- Update
- Update
About CDT Equity
Pharmaceutical Preparations
CDT Equity Inc. is a clinical-stage biopharmaceutical enterprise focused on identifying, acquiring, licensing, developing, and commercializing clinical pharmaceutical assets. The organization seeks to advance drug candidates targeting significant unmet medical needs, utilizing artificial intelligence and collaborative decision-support technologies to optimize its development pipeline and clinical decision-making. Its activities include conducting research, managing preclinical and clinical programs, and evaluating targeted therapeutics under collaboration and licensing arrangements.
Company profile, executives and historyCDT Equity stock: common questions
What is CDT Equity's stock price?
CDT closed at $0.51 on Nov 11, 2026, down 9.14% on the day. Over the past 52 weeks it traded between $0.17 and $355000.00.
What is CDT Equity's market cap?
CDT Equity was worth $401.20K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CDT's P/E ratio?
CDT Equity lost money over fiscal 2025 (diluted EPS -$1177.89), so it has no meaningful P/E ratio.
Does CDT Equity pay a dividend?
No. CDT Equity has not paid a cash dividend over the last twelve months.
How has CDT stock performed over the past year?
Including dividends, CDT returned -100.0% over the past year, against +12.4% for the S&P 500.
Who are CDT Equity's competitors?
Companies most similar to CDT Equity by business, industry and size include NBP, BDRX, OCS, ANL, SCNX.
See a number that looks wrong?